Market Place
Sourcing Support
Cardiff Oncology Announces Patent for Onvansertib in KRAS mCRC
19 Nov 2024 //
GLOBENEWSWIRE
Cardiff Oncology Reports Q3 2024 Results & Business Update
07 Nov 2024 //
GLOBENEWSWIRE
Cardiff Oncology Publishes DATA on KRAS Mutant mCRC Data
30 Oct 2024 //
GLOBENEWSWIRE
Cardiff Oncology Reports Q2 2024 Results And Business Update
08 Aug 2024 //
GLOBENEWSWIRE
Cardiff Oncology To Report Q2 2024 Results And Business Update
01 Aug 2024 //
GLOBENEWSWIRE
Cardiff Oncology to Present at the Jefferies Healthcare Conference
29 May 2024 //
GLOBENEWSWIRE
Cardiff Oncology to Present at Upcoming Investor Conferences in May
13 May 2024 //
GLOBENEWSWIRE
Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update
02 May 2024 //
GLOBENEWSWIRE
Cardiff Oncology Reports Q1 2024 Results, Business Update
25 Apr 2024 //
GLOBENEWSWIRE
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting
08 Apr 2024 //
GLOBENEWSWIRE
Cardiff Announces Upcoming Presentations at the AACR Annual Meeting 2024
06 Mar 2024 //
GLOBENEWSWIRE
Cardiff teases onvansertib efficacy in colorectal cancer
01 Mar 2024 //
ENDPTS
Cardiff Oncology Announces First Patient Dosed in Randomized First-line CRDF-004
29 Feb 2024 //
GLOBENEWSWIRE
Cardiff Oncology Provides Update on Ph 2 Randomized Second-line ONSEMBLE Trial
29 Feb 2024 //
GLOBENEWSWIRE
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results
29 Feb 2024 //
GLOBENEWSWIRE
Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference
26 Feb 2024 //
GLOBENEWSWIRE
Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results
22 Feb 2024 //
GLOBENEWSWIRE
Cardiff Announces Publication of Data from Phase 1b study in KRAS-mutated mCRC
17 Jan 2024 //
PR NEWSWIRE
Cardiff’s stock jumps after sharing promising PhII data for its PLK1 inhibitor
27 Sep 2023 //
ENDPTS
Cardiff Announces New Lead Program in First-Line Metastatic Colorectal Cancer
07 Aug 2023 //
PR NEWSWIRE
Cardiff Announces First Patient Dosed in ONSEMBLE Phase 2 Trial of Onvansertib
28 Mar 2023 //
PR NEWSWIRE
Cardiff Oncology Formally Introduces Scientific Advisory Board
06 Mar 2023 //
PR NEWSWIRE
Cardiff Oncology Reports Fourth Quarter and Full Year 2022 Results
02 Mar 2023 //
PR NEWSWIRE
Cardiff Oncology to Present at the Cowen 43rd Annual Health Care Conference
27 Feb 2023 //
PR NEWSWIRE
Cardiff Oncology Announces the Appointment of Fairooz Kabbinavar FACP, as CMO
02 Feb 2023 //
PR NEWSWIRE
Cardiff drops its lead prostate cancer program, sending shares into a tailspin
14 Sep 2022 //
ENPTS
Cardiff Oncology Announces Plans for a Randomized Trial in mCRC
12 Sep 2022 //
PRNEWSWIRE
Cardiff Oncology Announces Data from Program in KRAS-mutated mCRC
11 Sep 2022 //
PRNEWSWIRE
Cardiff Oncology to Present at Upcoming Investor Conferences in September
08 Sep 2022 //
PRNEWSWIRE
Cardiff Oncology Announces Upcoming Poster Presentations at ESMO Congress 2022
06 Sep 2022 //
PRNEWSWIRE
Cardiff Oncology Announces Departure of Chief Medical Officer
12 Apr 2022 //
PRNEWSWIRE
Cardiff Oncology Shows Data Showing Combo of PARP Inhibition with Onvansertib
08 Apr 2022 //
PRNEWSWIRE
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
31 Jan 2022 //
PRNEWSWIRE
Cardiff Oncology to Present at the B. Riley Securities 2022 Oncology Conference
20 Jan 2022 //
PRESS RELEASE
Cardiff Oncology to Present at the H.C. Wainwright BioConnect Virtual Conference
04 Jan 2022 //
PRESS RELEASE
Pfizer invests $15M in Cardiff to bankroll Amgen KRAS challenger
19 Nov 2021 //
PRECISIONONCOLOGYNEWS
Cardiff Oncology rises after reporting new data from colorectal cancer trial
08 Sep 2021 //
SEEKING ALPHA
Cardiff Oncology to Present New Data from Lead Clinical Program
25 Aug 2021 //
PRNEWSWIRE
Cardiff Oncology Reports Second Quarter 2021 Results
05 Aug 2021 //
PRNEWSWIRE
Cardiff Oncology Reports Second Quarter 2021 Results
05 Aug 2021 //
PRNEWSWIRE
Cardiff Oncology Announces Onvansertib Phase 1b/2 Data that Continues to
13 Apr 2021 //
PRNESWIRE
Cardiff Oncology Announces Onvansertib Phase 1b/2 Data that Continues
13 Apr 2021 //
PRNESWIRE
Cardiff Oncology Presents Phase 2 mCRPC Trial Data Showing a Two-Fold
11 Feb 2021 //
INVESTORROOM
Cardiff Oncology Presents Phase 2 mCRPC Trial Data Showing a Two-Fold Increase
11 Feb 2021 //
PRNEWSWIRE
Cardiff Receives "Study May Proceed" from FDA to Initiate Ph 2 of Onvansertib
26 Jan 2021 //
PRNEWSWIRE
Cardiff Receives "Study May Proceed" from FDA to Initiate Ph2 Trial Onvansertib
26 Jan 2021 //
PRNEWSWIRE
Cardiff Oncology Presents Data that Continues to Demonstrate Clinical Benefit
15 Jan 2021 //
INVESTORROOM
Cardiff Oncology Announces the Appointment of Dr. Rodney Markin
21 Dec 2020 //
PRNEWSWIRE
Cardiff Oncology Presents Data at ASH Demonstrating Safety and Anti-Leukemic
07 Dec 2020 //
PRNEWSWIRE
Cardiff Oncology prices equity offering at $13.50
29 Sep 2020 //
SEEKING ALPHA
Cardiff Oncology Presents Data at Confirming Efficacy of Onvansertib
17 Sep 2020 //
BIOSPACE
Cardiff Oncology to Present Data of Onvansertib in Mutated Colorectal Cancer
14 Sep 2020 //
BIOSPACE
Cardiff Oncology Data Continues to Demonstrate Efficacy, Safety of Onvansertib
15 Jun 2020 //
PRNEWSWIRE
Cardiff Oncology Announces Expanded Access Program for Onvansertib in KRAS
09 Jun 2020 //
PRNEWSWIRE
Cardiff Oncology Data Continues to Efficacy of Onvansertib in Patients
29 May 2020 //
PRNEWSWIRE
Cardiff Oncology Announces Fast Track Designation Granted by FDA to Onvansertib
28 May 2020 //
PRNEWSWIRE
